Companies › Halia Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 2; Neurology, Hematology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HT-4253 | – | Phase 2 | Alzheimers Disease | Feb 2028 |
| HT-6184 CD71 transferrin receptor antagonist | TFRC | Phase 2 | Myelodysplastic Syndrome | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07052006 | HT-6184 | Phase 2 | Myelodysplastic Syndrome | Hematology | Jan 2026 |
| NCT07399171 | HT-4253 | Phase 2 | Alzheimers Disease | Neurology | Feb 2028 |
Nuvig Therapeutics Biossil Actinogen Medical Abrexa Pharmaceuticals Imara
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.